One of the phase 3 trials was restricted to patients recently hospitalized with acute coronary syndromes,6 yet many cardiovascular events occurring early after acute coronary syndromes may relate to thrombotic mechanisms and not be modifiable through Lp-PLA2 inhibition. This evidence concerns the gene PLA2G7 and acute coronary syndrome.